Repeat biopsy is also recommended at progression in patients with breast cancer and NSCLC to capture targetable genomic changes such as ERBB2 (human epidermal growth factor receptor 2 [HER2]) copy number amplification (CNA) or EGFR and ALK resistance mutations, respectively.4,5,11. Here, ALK is linked to non-small cell lung carcinoma.